Sarcopenia in pancreatic cancer: Effect on patient outcomes

Pancreatic cancer is a challenging disease with an increasing incidence and extremely poor prognosis. The clinical outcomes of pancreatic cancer depend on tumor biology, responses to treatments, and malnutrition or cachexia. Sarcopenia represents a severe catabolic condition defined by the age-related loss of muscle mass and strength and affects as much as 70% of malnourished pancreatic cancer patients. The lumbar skeletal muscle index, defined as the total abdominal muscle area at the L3 vertebral level adjusted by the square of the height, is widely used for assessing sarcopenia in patients with pancreatic cancer. Several studies have suggested that sarcopenia may be a risk factor for perioperative complications and decreased recurrence-free or overall survival in patients with pancreatic cancer undergoing surgery. Sarcopenia could also intensify chemotherapy-induced toxicities and worsen the quality of life and survival in the neoadjuvant or palliative chemotherapy setting. Sarcopenia, not only at the time of diagnosis but also during treatment, decreases survival in patients with pancreatic cancer. Theoretically, multimodal interventions may improve sarcopenia and clinical outcomes; however, no study has reported positive results. Further prospective studies are needed to confirm the prognostic role of sarcopenia and the effects of multimodal interventions in patients with pancreatic cancer.

Automated summary

Pancreatic cancer is a challenging disease with a poor prognosis, and malnutrition with muscle wasting is common among patients. Muscle wasting not only increases the risk of postoperative complications, but also decreases the recurrence-free and overall survival. In addition, muscle wasting can intensify chemotherapy-induced toxicities and worsen the quality of life and survival. Further studies are needed to confirm the prognostic role of muscle wasting and the effects of multimodal interventions in patients with pancreatic cancer.